Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 ...
Artistic rendering of gene editing reagents — mRNA (red) and DNA (green and yellow) constructs — being packaged into a lipid nanoparticle (blue). UCLA researchers have developed a lipid ...
Morning Overview on MSN
Gene therapy targets rare cystic fibrosis mutation affecting ~10%
For roughly one in ten people living with cystic fibrosis, the drugs that have transformed survival for most CF patients are ...
Could next-generation gene editing mean a cure for cystic fibrosis (CF)? There's been a lot of advancement on the disease in the last decade, but there are still those living with the disease who get ...
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, ...
BETHESDA, Md.--(BUSINESS WIRE)--The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their gene editing collaboration with Intellia Therapeutics. The ...
Congenital bilateral absence of the vas deferens (CBAVD) is a recognised cause of male infertility most frequently linked to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ...
Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...
The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in adults and children 6 years and up ...
Cystic fibrosis is among the most common, known and studied genetic diseases. It affects over 100,000 people worldwide and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results